All In Biotech

Drug Trial Radar · NCT00549757

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality

Last checked: Nov 19, 2026Latest source record: Apr 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 8,606 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

8,606

Actual

Start

Oct 2007

Primary completion

Feb 2013

Study completion Feb 2013

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 26, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine whether, in patients with type 2 diabetes and pre-existing disease of the heart and the circulatory system and/or the kidney, aliskiren at a target dose of 300 mg once daily (compared to placebo), on top of conventional treatment, reduces death and disease caused by the heart, the circulatory system and the kidney. AMENDMENT 4 RATIONALE (MARCH 2012) : Protocol amendment 4 served to address the data monitoring committee recommendation dated 14 Dec 2011 to discontinue study treatment in all participating patients. It also addressed the subsequent Health Authorities request to implement a 12 month safety follow-up period (actual duration was 9 months in average) post study drug discontinuation.

Conditions

  • Type 2 Diabetes Mellitus
  • Cardiovascular Disease

Interventions

  • AliskirenDrug

    Aliskiren 150 mg film-coated tablets

  • PlaceboDrug

    Placebo to match aliskiren 150 mg film-coated tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Occurrence of Primary Composite Endpoint (Core : Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 months)
  2. Percentage of Participants With Cardiovascular (CV) Death (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 months)
  3. Percentage of Participants With Resuscitated Sudden Death (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 Months)
  4. Percentage of Participants With Fatal/Non-fatal Myocardial Infarction (MI) (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 Months)
  5. Percentage of Participants With Fatal/Non-fatal Stroke (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 Months)
  6. Percentage of Participants With Onset of End-stage Renal Disease (ESRD) (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 Months)
  7. Percentage of Participants With Doubling of Baseline Serum Creatinine Concentration, Sustained for at Least One Month (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 Months)
  8. Percentage of Participants With Unplanned Hospitalization for Heart Failure (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 Months)
  9. Percentage of Participants With All Cause Mortality (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 months)
  10. Percentage of Participants With Occurrence of Primary Composite Endpoint (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
  11. Percentage of Participants With Cardiovascular (CV) Death (Extension Phase)Time frame: from cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
  12. Percentage of Participants With Resuscitated Sudden Death (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
  13. Percentage of Participants Fatal/Non-fatal Myocardial Infarction (MI) (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 month in average)
  14. Percentage of Participants With Fatal/Non-fatal Stroke (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
  15. Percentage of Participants With Onset of End-stage Renal Disease (ESRD) (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
  16. Percentage of Participants Doubling of Baseline Serum Creatinine Concentration, Sustained for at Least One Month (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
  17. Percentage of Participants With Unplanned Hospitalization for Heart Failure (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
  18. Percentage of Participants With All Cause Mortality (Extension Phase)Time frame: from cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)

Locations

776 sites in 37 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Huntsville, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Montgomery, Alabama

  • Novartis Investigative Site

    Muscle Shoals, Alabama

  • Novartis Investigative Site

    Peoria, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Fayetteville, Arkansas

  • Novartis Investigative Site

    Burlingame, California

  • Novartis Investigative Site

    Fullerton, California

  • Novartis Investigative Site

    Huntington Beach, California

  • Novartis Investigative Site

    Oakland, California

  • Novartis Investigative Site

    Pasadena, California

  • Novartis Investigative Site

    Riverside, California

  • Novartis Investigative Site

    Spring Valley, California

  • Novartis Investigative Site

    Torrance, California

  • Novartis Investigative Site

    Walnut Creek, California

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Bridgeport, Connecticut

  • Novartis Investigative Site

    Aventura, Florida

  • Novartis Investigative Site

    Boca Raton, Florida

  • Novartis Investigative Site

    Fort Lauderdale, Florida

  • Novartis Investigative Site

    Hollywood, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Lauderdale Lakes, Florida

  • Novartis Investigative Site

    Pensacola, Florida

  • Novartis Investigative Site

    Plantation, Florida

  • Novartis Investigative Site

    West Palm Beach, Florida

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Augusta, Georgia

  • Novartis Investigative Site

    Augusta, Georgia

  • Novartis Investigative Site

    Cumming, Georgia

  • Novartis Investigative Site

    Honolulu, Hawaii

Showing 40 of 776 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.